{
  "symbol": "BIIB",
  "year": 2023,
  "period": "Y2023",
  "curated_text": "Symbol: BIIB. Year: 2023. Period: Y2023. ReportType: K10. Section: Competition and Market Position. This section discusses competitors, market dynamics, and regulatory landscape.  Competitors mentioned: COVID-19, Solothurn, Biogen Inc., MabThera, PLEGRIDY \u00ae, TYSABRI \u00ae, Biogen, BENEPALI, FLIXABI, FUMADERM, IMRALDI, FAMPYRA, HUMIRA \u00ae, LEQEMBI, LUNSUMIO, BUSINESS Overview Biogen, SMA, TECFIDERA, VUMERITY, AVONEX, TYSABRI, Eisai Co., Ltd., Eisai, the U.S. Food and Drug Administration, FDA, non-Hodgkin's, CLL, Genentech, Inc., Genentech, the Roche Group, MDD, ALS, ENBREL, HUMIRA, BYOOVIZ, Key Business Developments, Key Collaborative Relationships Eisai Collaboration Agreements LEQEMBI, Biologics License Application, the European Medicines Agency, EMA, the Marketing Authorization Application, MAA, the Pharmaceuticals and Medical Devices Agency, Priority Review, the Japanese Ministry of Health, Labor and, Welfare, BLA, the National Medicinal Products Administration, NMPA, Sage Therapeutics, Inc., PPD, a New Drug Application, NDA, the European Commission, EC, Alcyone Therapeutics (Alcyone, ThecaFlex, Alcyone, Joint Venture, Samsung BioLogics, Samsung BioLogics Co., Ltd., Cost Saving Initiatives, MA, Plant and Equipment, Pharmaceutical Operations and Technology, Board of Directors Update \u2022, Board of Directors, Pipeline Developments Multiple Sclerosis, the European Patent Office, the Advocate General of the Court of Justice of the European Union, CJEU, the European General Court, The New England Journal of Medicine, The Journal of Prevention of Alzheimer's, Phase 3 EMERGE, ENGAGE, Medicare, Medicaid Services, CMS, NCD, the European College of Neuropsychopharmacology, Congress, ASCEND, ASO, VALOR, BIIB122, LRRK2, Denali Therapeutics Inc., Denali, Alectos Therapeutics Inc., CLE, SLE, Xbrane Biopharma AB, CIMZIA, Bio-Thera Solutions, Ltd., Bio-Thera, Annual European Congress of Rheumatology, Ionis Pharmaceuticals Inc., TGN, DPN, InnoCare Pharma Limited, InnoCare, Bruton, Segment Information, Management's Discussion and Analysis of Financial Condition, RRMS, Alkermes plc, E.U. None U.S., MS Acorda Therapeutics, Inc., Acorda, Alkermes, Neuromuscular Disorders SMA, SMN1, survival motor neuron, SMN, Eisai U.S. Alzheimer's, Eisai U.S., TNF, Product Indication Major Markets Rheumatoid, Juvenile, Psoriatic, Axial, U.K. Rheumatoid, Psoriasis Paediatric, Crohn\u2019s, Ulcerative colitis Paediatric, France Germany Italy Neovascular, Product Indication Major Markets Non-Hodgkin's, CLL Rheumatoid, ANCA, Pemphigus, Non-Hodgkin's, CLL Follicular, None Germany Patient Support and Access, Early Access Programs, PLEGRIDY, Trademark Office, the Hatch-Waxman Act, the World Trade Organization's, USPTO, Europe 2,236,154 Formulation, FAMPYRA Europe, Sustained, Crystalline, U.S. 8,361,977 Compositions, U.S. 8,980,853 Compositions, U.S. 9,717,750 Compositions, U.S. 9,926,559 Compositions, Europe 1,910,395 Compositions, Europe 2,548,560 Compositions, Europe 3,305,302 Compositions, Europe 3,308,788 Compositions, Europe 3,449,926 Compositions, LEQEMBI U.S. 8,025,878, E.U. 2024, LEQEMBI U.S. 2035, Litigation, inter partes, Sanofi Genzyme BETASERON/BETAFERON, Bayer Group BRIUMVI, TG Therapeutics, Inc. COPAXONE, glatiramer acetate, Teva Pharmaceuticals Industries Ltd., EXTAVIA, Novartis AG, fingolimod, Sandoz, Johnson & Johnson REBIF, ozanimod, Banner Life Sciences KESIMPTA, Novartis AG Multiple, the General Court\u2019s, the Advocate General of the CJEU, RMS, PPMS, OCREVUS, TREANDA, HCL, ARZERRA, IMBRUVICA, ZYDELIG, Rheumatoid Arthritis, ORENCIA, Phase 3 Aducanumab, Phase 1 Neuropsychiatry Zuranolone, the U.S. Zuranolone, ALS Filed, Phase 3 BIIB122 (DNL151, SUR1-TRPM4 Inhibitor, Large Hemispheric Infarction, LHI, Business Relationships, Eisai Co., Eisai for ADUHELM, the U.S. Outside, Ionis Pharmaceuticals, Roche Group, Denali\u2019s Transport, Antibody Transport Vehicle, ATV, Transport Vehicle, Samsung Bioepis Co., Ltd., UCB, Sangamo Therapeutics, Inc., Sangamo. Context excerpt: competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate strategy; \u2022 the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions and cost-reduction measures; \u2022 the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, ",
  "competition_summary": [
    {
      "competitor": "COVID-19",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Solothurn",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Biogen Inc.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "MabThera",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "PLEGRIDY \u00ae",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "TYSABRI \u00ae",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Biogen",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "BENEPALI",
      "mentions": 8,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "FLIXABI",
      "mentions": 9,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "FUMADERM",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "IMRALDI",
      "mentions": 6,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "FAMPYRA",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "HUMIRA \u00ae",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "LEQEMBI",
      "mentions": 17,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "LUNSUMIO",
      "mentions": 7,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "BUSINESS Overview Biogen",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "SMA",
      "mentions": 18,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "TECFIDERA",
      "mentions": 18,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "VUMERITY",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "AVONEX",
      "mentions": 6,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "TYSABRI",
      "mentions": 7,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Eisai Co., Ltd.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Eisai",
      "mentions": 23,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "the U.S. Food and Drug Administration",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "FDA",
      "mentions": 15,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "non-Hodgkin's",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "CLL",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Genentech, Inc.",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Genentech",
      "mentions": 13,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "the Roche Group",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "MDD",
      "mentions": 7,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "ALS",
      "mentions": 5,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "ENBREL",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "HUMIRA",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "BYOOVIZ",
      "mentions": 8,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Key Business Developments",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Key Collaborative Relationships Eisai Collaboration Agreements LEQEMBI",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Biologics License Application",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "the European Medicines Agency",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "EMA",
      "mentions": 8,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "the Marketing Authorization Application",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "MAA",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "the Pharmaceuticals and Medical Devices Agency",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Priority Review",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "the Japanese Ministry of Health, Labor and",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Welfare",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "BLA",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "the National Medicinal Products Administration",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "NMPA",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Sage Therapeutics, Inc.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "PPD",
      "mentions": 6,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "a New Drug Application",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "NDA",
      "mentions": 7,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "the European Commission",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "EC",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Alcyone Therapeutics (Alcyone",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "ThecaFlex",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Alcyone",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Joint Venture",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Samsung BioLogics",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Samsung BioLogics Co., Ltd.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Cost Saving Initiatives",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "MA",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Plant and Equipment",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Pharmaceutical Operations and Technology",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Board of Directors Update \u2022",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Board of Directors",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Pipeline Developments Multiple Sclerosis",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "the European Patent Office",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "the Advocate General of the Court of Justice of the European Union",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "CJEU",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "the European General Court",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "The New England Journal of Medicine",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "The Journal of Prevention of Alzheimer's",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Phase 3 EMERGE",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "ENGAGE",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Medicare",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Medicaid Services",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "CMS",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "NCD",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "the European College of Neuropsychopharmacology",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Congress",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "ASCEND",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "ASO",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "VALOR",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "BIIB122",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "LRRK2",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Denali Therapeutics Inc.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Denali",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Alectos Therapeutics Inc.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "CLE",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "SLE",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Xbrane Biopharma AB",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "CIMZIA",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Bio-Thera Solutions, Ltd.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Bio-Thera",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Annual European Congress of Rheumatology",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Ionis Pharmaceuticals Inc.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "TGN",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "DPN",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "InnoCare Pharma Limited",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "InnoCare",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Bruton",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Segment Information",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Management's Discussion and Analysis of Financial Condition",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "RRMS",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Alkermes plc",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "E.U. None U.S.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "MS Acorda Therapeutics, Inc.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Acorda",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Alkermes",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Neuromuscular Disorders SMA",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "SMN1",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "survival motor neuron",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "SMN",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Eisai U.S. Alzheimer's",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Eisai U.S.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "TNF",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Product Indication Major Markets Rheumatoid",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Juvenile",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Psoriatic",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Axial",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "U.K. Rheumatoid",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Psoriasis Paediatric",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Crohn\u2019s",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Ulcerative colitis Paediatric",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "France Germany Italy Neovascular",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Product Indication Major Markets Non-Hodgkin's",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "CLL Rheumatoid",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "ANCA",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Pemphigus",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Non-Hodgkin's",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "CLL Follicular",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "None Germany Patient Support and Access",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Early Access Programs",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "PLEGRIDY",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Trademark Office",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "the Hatch-Waxman Act",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "the World Trade Organization's",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "USPTO",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Europe 2,236,154 Formulation",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "FAMPYRA Europe",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Sustained",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Crystalline",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "U.S. 8,361,977 Compositions",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "U.S. 8,980,853 Compositions",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "U.S. 9,717,750 Compositions",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "U.S. 9,926,559 Compositions",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Europe 1,910,395 Compositions",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Europe 2,548,560 Compositions",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Europe 3,305,302 Compositions",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Europe 3,308,788 Compositions",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Europe 3,449,926 Compositions",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "LEQEMBI U.S. 8,025,878",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "E.U. 2024",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "LEQEMBI U.S. 2035",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Litigation",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "inter partes",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Sanofi Genzyme BETASERON/BETAFERON",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Bayer Group BRIUMVI",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "TG Therapeutics, Inc. COPAXONE",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "glatiramer acetate",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Teva Pharmaceuticals Industries Ltd.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "EXTAVIA",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Novartis AG",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "fingolimod",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Sandoz",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Johnson & Johnson REBIF",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "ozanimod",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Banner Life Sciences KESIMPTA",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Novartis AG Multiple",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "the General Court\u2019s",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "the Advocate General of the CJEU",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "RMS",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "PPMS",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "OCREVUS",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "TREANDA",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "HCL",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "ARZERRA",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "IMBRUVICA",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "ZYDELIG",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Rheumatoid Arthritis",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "ORENCIA",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Phase 3 Aducanumab",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Phase 1 Neuropsychiatry Zuranolone",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "the U.S. Zuranolone",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "ALS Filed",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Phase 3 BIIB122 (DNL151",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "SUR1-TRPM4 Inhibitor",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Large Hemispheric Infarction",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "LHI",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Business Relationships",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Eisai Co.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Eisai for ADUHELM",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "the U.S. Outside",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Ionis Pharmaceuticals",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Roche Group",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Denali\u2019s Transport",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Antibody Transport Vehicle",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "ATV",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Transport Vehicle",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Samsung Bioepis Co., Ltd.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "UCB",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Sangamo Therapeutics, Inc.",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    },
    {
      "competitor": "Sangamo",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementa"
    }
  ]
}